Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
29 hedge funds and large institutions have $706K invested in Navidea Biopharmaceuticals Inc. in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
275% more call options, than puts
Call options by funds: $60K | Put options by funds: $16K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
4% more funds holding
Funds holding: 28 → 29 (+1)
9% less capital invested
Capital invested by funds: $772K → $706K (-$66.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$220K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$214K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
+$19.2K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$5.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$32.9K |
| 2 |
JP Morgan Chase
New York
|
-$6.57K |
| 3 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$3.97K |
| 4 |
Morgan Stanley
New York
|
-$110 |
NAVB Hedge Fund Activity: Q1 2020 in Review
29 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2020, worth a combined $706K — down 8.6% from $772K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NAVB positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $220K. The largest seller was Group One Trading, exiting entirely with an estimated $32.9K sold.
- 29 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2020, up from 28 in Q4 2019.
- Funds reported $706K of Navidea Biopharmaceuticals Inc. stock for Q1 2020, down 8.6% quarter-over-quarter.
- 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2020 and 3 closed out, a net change of +3 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2020 was FNY Investment Advisers, an estimated $220K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2020 was Group One Trading, an estimated $32.9K sold.
Based on aggregated 13F filings for Q1 2020.